HRP970641A2 - Fused bicyclic pyrimidine derivatives - Google Patents

Fused bicyclic pyrimidine derivatives

Info

Publication number
HRP970641A2
HRP970641A2 HR60/041,846A HRP970641A HRP970641A2 HR P970641 A2 HRP970641 A2 HR P970641A2 HR P970641 A HRP970641 A HR P970641A HR P970641 A2 HRP970641 A2 HR P970641A2
Authority
HR
Croatia
Prior art keywords
phenyl
alkyl
pyrrolo
cancer
compound
Prior art date
Application number
HR60/041,846A
Other languages
English (en)
Croatian (hr)
Inventor
Susan Beth Sobolov-Jaynes
Original Assignee
Susan Beth Sobolov-Jaynes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Susan Beth Sobolov-Jaynes filed Critical Susan Beth Sobolov-Jaynes
Publication of HRP970641A2 publication Critical patent/HRP970641A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR60/041,846A 1996-11-27 1997-11-26 Fused bicyclic pyrimidine derivatives HRP970641A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3186296P 1996-11-27 1996-11-27
US4184697P 1997-04-09 1997-04-09

Publications (1)

Publication Number Publication Date
HRP970641A2 true HRP970641A2 (en) 1998-10-31

Family

ID=26707706

Family Applications (1)

Application Number Title Priority Date Filing Date
HR60/041,846A HRP970641A2 (en) 1996-11-27 1997-11-26 Fused bicyclic pyrimidine derivatives

Country Status (24)

Country Link
US (1) US6413971B1 (id)
EP (1) EP0946554A1 (id)
JP (1) JP2000505109A (id)
KR (1) KR20000057228A (id)
CN (1) CN1237177A (id)
AP (1) AP9701146A0 (id)
AR (1) AR010740A1 (id)
AU (1) AU4718997A (id)
BG (1) BG103417A (id)
BR (1) BR9713552A (id)
CA (1) CA2272705C (id)
CO (1) CO4650037A1 (id)
HN (1) HN1997000146A (id)
HR (1) HRP970641A2 (id)
ID (1) ID18958A (id)
IL (1) IL129825A0 (id)
IS (1) IS5041A (id)
MA (1) MA26452A1 (id)
NO (1) NO992524L (id)
OA (1) OA11051A (id)
PA (1) PA8442001A1 (id)
PE (1) PE17299A1 (id)
TN (1) TNSN97192A1 (id)
WO (1) WO1998023613A1 (id)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888349B1 (en) * 1996-01-23 2002-05-22 Novartis AG Pyrrolopyrimidines and processes for their preparation
DK0880508T3 (da) 1996-02-13 2003-06-30 Astrazeneca Ab Quinazolinderivater som VEGF-inhibitorer
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ATE300521T1 (de) 1996-09-25 2005-08-15 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1087970B1 (en) 1998-06-19 2004-04-28 Pfizer Products Inc. PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
TR200201051T2 (tr) 1999-10-19 2002-09-23 Merck & Co., Inc. Tirosin kinaz inhibitörleri.
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1676845B1 (en) 1999-11-05 2008-06-11 AstraZeneca AB New quinazoline derivatives
KR100477818B1 (ko) 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-ｄ] 피리미딘 화합물
EP1244672B1 (en) 1999-12-21 2005-07-20 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2001094353A1 (en) 2000-06-06 2001-12-13 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
HRP20021000A2 (en) 2000-06-26 2005-02-28 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
DE60113286T2 (de) 2000-10-17 2006-06-22 Merck & Co., Inc. Oral aktive salze mit tyrosinkinaseaktivität
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
CN100525768C (zh) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7169788B2 (en) 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003062209A2 (en) * 2002-01-17 2003-07-31 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
CA2478050A1 (en) 2002-03-01 2003-09-12 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CN1717236A (zh) 2002-11-26 2006-01-04 辉瑞产品公司 治疗移植排斥的方法
EP1569925A1 (en) * 2002-12-13 2005-09-07 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
US7329664B2 (en) * 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
US20070105865A1 (en) * 2003-09-09 2007-05-10 Neurogen Corporation Substituted bicyclic quinazolin-4-ylamine derivatives
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
EP1687309A1 (en) 2003-11-17 2006-08-09 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
KR100807920B1 (ko) 2003-12-23 2008-02-27 화이자 인코포레이티드 신규한 퀴놀린 유도체
CA2566160C (en) 2004-05-27 2011-01-18 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
BRPI0511768A (pt) * 2004-06-02 2008-01-08 Takeda Pharmaceutical composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto
ZA200610669B (en) * 2004-06-02 2008-06-25 Takeda Pharmaceutical Fused heterocyclic compound
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US7541367B2 (en) * 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
CA2633752A1 (en) * 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
WO2007076034A2 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
WO2007076035A2 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
TW200738707A (en) * 2005-12-21 2007-10-16 Abbott Lab Anti-viral compounds
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US20100004238A1 (en) 2006-12-12 2010-01-07 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CA2672737A1 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
EP2222162B1 (en) * 2007-11-28 2016-11-16 Dana-Farber Cancer Institute, Inc. Small molecule myristate inhibitors of bcr-abl and methods of use
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
CA2733359C (en) 2008-08-20 2014-08-05 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
ME02359B (me) 2009-08-19 2016-06-20 Eisai R&D Man Co Ltd Farmaceutska kompozicija koja sadrži derivate hinolina
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
EP2670244B1 (en) 2011-02-04 2018-04-11 Duquesne University of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
WO2013174735A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
MD20140130A2 (ro) * 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2900670A1 (en) 2012-09-26 2015-08-05 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
EP2900671A1 (en) 2012-09-26 2015-08-05 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
WO2014085528A1 (en) 2012-11-29 2014-06-05 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
PL3177612T3 (pl) 2014-08-04 2022-08-08 Nuevolution A/S Opcjonalnie skondensowane pochodne pirymidyny podstawione heterocyklilem, użyteczne w leczeniu chorób zapalnych, metabolicznych, onkologicznych i autoimmunologicznych
JO3783B1 (ar) 2014-08-28 2021-01-31 Eisai R&D Man Co Ltd مشتق كوينولين عالي النقاء وطريقة لإنتاجه
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
AU2016272881C1 (en) 2015-06-04 2019-10-03 Pfizer Inc. Solid dosage forms of palbociclib
JP6757959B2 (ja) 2015-06-16 2020-09-23 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ 抗がん剤
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
MX377305B (es) 2015-09-14 2025-03-07 Pfizer DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2.
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
US10233188B2 (en) 2016-08-15 2019-03-19 Pfizer Inc. CDK2/4/6 inhibitors
ES2971448T3 (es) 2017-02-08 2024-06-05 Eisai R&D Man Co Ltd Composición farmacéutica para el tratamiento de tumores
MX2019013014A (es) 2017-05-16 2020-08-06 Eisai R&D Man Co Ltd Tratamiento de carcinoma hepatocelular.
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
KR20220053557A (ko) 2019-07-17 2022-04-29 2692372 온타리오 인크. 벤젠술폰아미드 유도체 및 그의 용도
NZ786543A (en) 2019-12-20 2026-01-30 Nuevolution As Compounds active towards nuclear receptors
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
KR19990067704A (ko) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
CZ288955B6 (cs) * 1994-02-23 2001-10-17 Pfizer Inc. Substituované chinazolinové deriváty, jejich pouľití a farmaceutické prostředky na jejich bázi
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
JPH089637A (ja) * 1994-06-20 1996-01-12 Shindengen Electric Mfg Co Ltd Ｆｅｔによる出力スイッチの駆動回路
NZ304859A (en) * 1995-04-03 2000-01-28 Novartis Ag 4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives, medicaments and processes for the preparation thereof
US5804685A (en) * 1995-06-07 1998-09-08 Neurogen Corporation Deazapurine derivatives: a new class of CRF1 specific ligands
US5644057A (en) * 1995-05-12 1997-07-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
JPH08329674A (ja) * 1995-06-02 1996-12-13 Hitachi Ltd 半導体装置
DE69531558T2 (de) 1995-06-07 2004-03-18 Pfizer Inc. Heterocyclische kondensierte pyrimidin-derivate
CN1100778C (zh) * 1995-07-06 2003-02-05 诺瓦蒂斯有限公司 吡咯并嘧啶及其制备方法
WO1998023616A1 (en) * 1996-11-26 1998-06-04 American Cyanamid Company Biaryl-pyridoquinazolinone derivatives as anti-cancer agents

Also Published As

Publication number Publication date
HN1997000146A (es) 1998-02-26
US6413971B1 (en) 2002-07-02
TNSN97192A1 (fr) 2005-03-15
BG103417A (en) 2000-06-30
OA11051A (en) 2003-03-07
WO1998023613A1 (en) 1998-06-04
CO4650037A1 (es) 1998-09-03
AP9701146A0 (en) 1998-01-31
EP0946554A1 (en) 1999-10-06
CN1237177A (zh) 1999-12-01
CA2272705C (en) 2003-03-18
NO992524D0 (no) 1999-05-26
IL129825A0 (en) 2000-02-29
JP2000505109A (ja) 2000-04-25
KR20000057228A (ko) 2000-09-15
CA2272705A1 (en) 1998-06-04
BR9713552A (pt) 2000-01-25
NO992524L (no) 1999-05-26
PA8442001A1 (es) 2000-05-24
AU4718997A (en) 1998-06-22
IS5041A (is) 1999-04-30
PE17299A1 (es) 1999-02-19
ID18958A (id) 1998-05-28
AR010740A1 (es) 2000-07-12
US20020045630A1 (en) 2002-04-18
MA26452A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
HRP970641A2 (en) Fused bicyclic pyrimidine derivatives
RU2136683C1 (ru) Сконденсированные с гетероциклическим кольцом производные пиримидина
US6395733B1 (en) Heterocyclic ring-fused pyrimidine derivatives
KR101483215B1 (ko) 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
US6492383B1 (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
JP3457164B2 (ja) アミノキナゾリン誘導体
EP1807424B1 (en) Novel kinase inhibitors
PL201784B1 (pl) Pochodne benzimidazolu, ich zastosowanie i środek farmaceutyczny
WO2009077956A2 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Нh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
CA2630164A1 (en) 3-(substituted amino)-pyrazolo[3,4-d]pyrimidines as ephb and vegfr2 kinase inhibitors
JP2018528193A (ja) インドール誘導体、その調製方法および医薬におけるその使用
CN106146493A (zh) 吡唑并[3,4-b]吡啶类和吲唑类化合物的制备方法和用途
CN107459519A (zh) 稠合嘧啶哌啶环衍生物及其制备方法和应用
MXPA00004491A (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 19981126

Year of fee payment: 2

ODBI Application refused